Good morning :)
$
₹
Palatin Technologies, Inc. Common Stock

Palatin Technologies, Inc. Common Stock

PTN

NASDAQ
Asset Logo

Palatin Technologies, Inc. Common Stock

PTN

NASDAQ
$5.413.63% (+0.19)
$
₹
$5.413.63% (+0.19)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $8.9M the stock is ranked 5754

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.33
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.96
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.62
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-63.54%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 3 analysts reports

Buy
3 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+924.9%

Earnings Growth

+93.21%

Rev. Growth

-34.65%

See Detailed Forecast

Company Profile

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
36.27%
36.27%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
58.2%
58.2%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
37.21%
37.21%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
24.59%
24.59%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
51.74%
51.74%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 924.90% growth, versus a trailing 3-year CAGR of 35.03%.

2026
Current$5.22Baseline
Analyst Target - 1 year
Target$53.5+924.9%

All values in $

202220232024202520262027$15.46$29.92$44.39Target+924.9%
2026
Current$5.22Baseline
Analyst Target - 1 year
Target$53.5+924.9%

All values in $

Revenue Forecast

Revenue Forecast

2026
Current$13.18Baseline
Forecast for Jun 2027
High$15+13.77%
Average$8.61-34.65%
Low$3-77.25%

All values in $ Million

2022202320242025202620271.464.854.49013.18Low-77.25%Average-34.65%High+13.77%
2026
Current$13.18Baseline
Forecast for Jun 2027
High$15+13.77%
Average$8.61-34.65%
Low$3-77.25%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2026
Current$-35.5Baseline
Forecast for Jun 2027
High$-2.02+94.31%
Average$-2.41+93.21%
Low$-2.8+92.11%

All values in $

20222023202420262027-89.59-83.11-79-35.5Low+92.11%Average+93.21%High+94.31%
2026
Current$-35.5Baseline
Forecast for Jun 2027
High$-2.02+94.31%
Average$-2.41+93.21%
Low$-2.8+92.11%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

8.8
4.6
0.1
-7.2
3.9
-1.4
0.3
-4.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00.3500008.840.113.920.30
Net Income-8.43-8.25-7.82-2.44-4.81-2.224.67-7.26-1.43-4.35
Net Profit Margin--2357.26%----52.86%-6260.00%-36.54%-1449.14%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Palatin Technologies, Inc. Common Stock -1.331.62
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare PTN with any stock or ETF
Compare PTN with any stock or ETF
Comparing from
PTN
ABBV
AMGN
Loading...

Frequently asked questions

  1. Palatin Technologies, Inc. Common Stock (PTN) share price today is $5.41 as of November 5, 2026 at 12:22 AM IST. The stock touched a day high of $5.59 and a day low of $5.33.

  2. Palatin Technologies, Inc. Common Stock stock trades on NASDAQ under the ticker symbol PTN.

  3. Palatin Technologies, Inc. Common Stock's market capitalization is $8.88M as of November 5, 2026 at 12:22 AM IST.

  4. Palatin Technologies, Inc. Common Stock's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Palatin Technologies, Inc. Common Stock's price-to-book (P/B) ratio is 1.33 as of November 4, 2026.

  6. Yes, You can buy Palatin Technologies, Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Palatin Technologies, Inc. Common Stock shares in three steps: 1. Search Palatin Technologies, Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Palatin Technologies, Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Palatin Technologies, Inc. Common Stock (PTN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.8484 shares at the current price of $5.41.

Loading...